NURO - NeuroMetrix
$4.31 -1.19 (-21.64%)Updated: 09:06 May 23, 2022 EST
|Curr. Week||Curr. Month||Curr. Quarter||Next Quarter||Curr Year||13.45||1.23||0.27||-0.96||-0.88|
CURRENT VOLATILITY RANK
Variation from the lowest to the highest value in a period.
|Curr. Week||Curr. Month||Curr. Quarter||Next Quarter||Curr Year||37.41||10.35||6.01||5.69||5.64|
The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.
|Curr. Week||Next Week||Curr. Month||Curr. Quarter||50%||55.76%||55.76%||55.76%|
MOVING AVERAGE METRIC
|5 Sessions||Change 5 Sessions||20 Sessions||Change 20 Sessions||50 Sessions||Change 50 Sessions||200 Sessions||4.7||-8.56%||5.14||-14.62%||6.02||-29.43%||8.53|
|RS Hour||RSI Hour||RS Day||RSI Day||N/A||N/A||1.5||-1|
NeuroMetrix Technical Analysis News
NeuroMetrix Stock Over 21% Down At Session Start Today
(VIANEWS) - Shares of NeuroMetrix (NASDAQ: NURO) fell by a staggering 21.64% to $4.31 at 10:46 EST on Monday, following the last session's downward trend. NASDAQ is falling 0.3% to $11,354.62, after three sequential sessions in a row of losses. This seems, up until now, a somewhat negative trend trading session today.NeuroMetrix's last close was $4.31, 88.88% below its 5...
At May 23, 2022, 9:47 am
|Industry:||Medical Instruments & Supplies|
|F. Time Employees:||20|
NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; ADVANCE system, a platform for the performance of traditional nerve conduction studies; and SENSUS, a pain therapy device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain. The company offers its products to consumers, retail merchandisers, direct response TV promoters, health care professionals, managed care organizations, endocrinologists, podiatrists, physicians, neurologists, and physical medicine and rehabilitation centers, as well as primary care, internal medicine, orthopedic, hand, and neurosurgeons. It operates in the United States, Europe, Japan, China, the Middle East, and Mexico. The company has a strategic collaboration with GlaxoSmithKline. NeuroMetrix, Inc. was founded in 1996 and is based in Woburn, Massachusetts.
NeuroMetrix, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.